Caveolin-1 is essential for glimepiride-induced insulin secretion in the pancreatic betaTC-6 cell line - PubMed (original) (raw)
. 2008 Oct 17;375(2):235-7.
doi: 10.1016/j.bbrc.2008.08.003. Epub 2008 Aug 12.
Affiliations
- PMID: 18703018
- DOI: 10.1016/j.bbrc.2008.08.003
Caveolin-1 is essential for glimepiride-induced insulin secretion in the pancreatic betaTC-6 cell line
A Puddu et al. Biochem Biophys Res Commun. 2008.
Abstract
The K(ATP) channels play a pivotal role in the complex mechanism of insulin secretion. K(ATP) channels represent the target of sulphonylureas, a class of drugs widely used in type 2 diabetes to stimulate insulin secretion. We previously showed that caveolin-1 depletion impairs action of the sulphonylurea glimepiride in human endothelial cells. The aim of this work was to investigate the possible role of caveolin-1 in glimepiride-induced insulin secretion. Caveolin-1 was depleted using siRNA method in the pancreatic betaTC-6 cell line. Then stimulation of insulin secretion was performed with different secretagogues (glucose, KCl, and glimepiride). Here, we show that betaTC-6 caveolin-1 depleted cells maintained high rate of insulin secretion after KCl, but not after glucose and glimepiride stimulation. Moreover, we find a direct interaction between caveolin-1 and Kir6.2, one of the K(ATP) channel subunit. These results demonstrate that Cav-1 plays a critical role for glucose and sulfonylurea-stimulated insulin secretion.
Similar articles
- Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells.
Remedi MS, Nichols CG. Remedi MS, et al. PLoS Med. 2008 Oct 28;5(10):e206. doi: 10.1371/journal.pmed.0050206. PLoS Med. 2008. PMID: 18959471 Free PMC article. - Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide.
McClenaghan NH, Flatt PR, Ball AJ. McClenaghan NH, et al. J Endocrinol. 2006 Sep;190(3):889-96. doi: 10.1677/joe.1.06949. J Endocrinol. 2006. PMID: 17003289 - Treating diabetes today: a matter of selectivity of sulphonylureas.
Seino S, Takahashi H, Takahashi T, Shibasaki T. Seino S, et al. Diabetes Obes Metab. 2012 Jan;14 Suppl 1:9-13. doi: 10.1111/j.1463-1326.2011.01507.x. Diabetes Obes Metab. 2012. PMID: 22118705 Review. - Inhibition of K+ channels and stimulation of insulin secretion by the sulfonylurea, glimepiride, in relation to its membrane binding in pancreatic islets.
Schwanstecher M, Mnner K, Panten U. Schwanstecher M, et al. Pharmacology. 1994 Aug;49(2):105-11. doi: 10.1159/000139222. Pharmacology. 1994. PMID: 7972319 - [Pharmacology of glimepiride].
Satoh Y. Satoh Y. Nihon Rinsho. 1997 Nov;55 Suppl:147-51. Nihon Rinsho. 1997. PMID: 9434459 Review. Japanese. No abstract available.
Cited by
- Release of Matrix Metalloproteinases-2 and 9 by S-Nitrosylated Caveolin-1 Contributes to Degradation of Extracellular Matrix in tPA-Treated Hypoxic Endothelial Cells.
Song H, Cheng Y, Bi G, Zhu Y, Jun W, Ma W, Wu H. Song H, et al. PLoS One. 2016 Feb 16;11(2):e0149269. doi: 10.1371/journal.pone.0149269. eCollection 2016. PLoS One. 2016. PMID: 26881424 Free PMC article. - Caveolin: A New Link Between Diabetes and AD.
Surguchov A. Surguchov A. Cell Mol Neurobiol. 2020 Oct;40(7):1059-1066. doi: 10.1007/s10571-020-00796-4. Epub 2020 Jan 23. Cell Mol Neurobiol. 2020. PMID: 31974905 Review. - Emerging Role of Caveolin-1 in GLP-1 Action.
Puddu A, Maggi D. Puddu A, et al. Front Endocrinol (Lausanne). 2021 Apr 14;12:668012. doi: 10.3389/fendo.2021.668012. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33935978 Free PMC article. Review. - Role of Caveolin-1 in Diabetes and Its Complications.
Haddad D, Al Madhoun A, Nizam R, Al-Mulla F. Haddad D, et al. Oxid Med Cell Longev. 2020 Jan 27;2020:9761539. doi: 10.1155/2020/9761539. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32082483 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases